Sugi Predict

Sugi Predict / Targets / NECTIN4

NECTIN4

Nectin-4 · Q96NY8 · NECTIN4 on Sugi Atlas →

3,235 patent compounds predicted against NECTIN4, 2,330 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15507436 SCHEMBL15507436 0.37 12/20
SCHEMBL8733400 SCHEMBL8733400 0.55 11/20
SCHEMBL8259896 SCHEMBL8259896 0.41 11/20
SCHEMBL8260113 SCHEMBL8260113 0.41 11/20
SCHEMBL13267853 SCHEMBL13267853 0.36 11/20
SCHEMBL14275196 SCHEMBL14275196 0.41 10/20
SCHEMBL14275199 SCHEMBL14275199 0.39 10/20
SCHEMBL14274752 SCHEMBL14274752 0.42 9/20
SCHEMBL8256875 SCHEMBL8256875 0.41 9/20
SCHEMBL13267659 SCHEMBL13267659 0.38 9/20
SCHEMBL13246868 SCHEMBL13246868 0.37 9/20
SCHEMBL15177343 SCHEMBL15177343 0.37 9/20
SCHEMBL12582357 SCHEMBL12582357 0.47 8/20
SCHEMBL14274790 SCHEMBL14274790 0.39 8/20
SCHEMBL13555149 SCHEMBL13555149 0.37 8/20
SCHEMBL14274721 SCHEMBL14274721 0.39 7/20
SCHEMBL14446707 SCHEMBL14446707 0.37 7/20
SCHEMBL14274751 SCHEMBL14274751 0.43 6/20
SCHEMBL14274754 SCHEMBL14274754 0.43 6/20
SCHEMBL14274706 SCHEMBL14274706 0.42 6/20

Clinical trials — most relevant to NECTIN4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors PHASE2/PHASE3RECRUITING
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) PHASE2RECRUITING
Study of EV for Recurrent Endometrial Carcinoma PHASE2NOT_YET_RECRUITING
Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy PHASE2RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors PHASE1/PHASE2RECRUITING
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) PHASE2RECRUITING
PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients PHASE2RECRUITING
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis PHASE2RECRUITING
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) PHASE2ACTIVE_NOT_RECRUITING
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors PHASE1/PHASE2WITHDRAWN
Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01) PHASE2NOT_YET_RECRUITING
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology PHASE2RECRUITING
A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI PHASE2NOT_YET_RECRUITING
JS207 Combination Therapy in Triple-negative Breast Cancer PHASE2RECRUITING
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer PHASE2RECRUITING
Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors PHASE1UNKNOWN
Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 PHASE1ENROLLING_BY_INVITATION
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma PHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors PHASE1RECRUITING
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer PHASE1RECRUITING
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18) PHASE1NOT_YET_RECRUITING
Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T) PHASE1UNKNOWN
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 PHASE1COMPLETED
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy PHASE1ACTIVE_NOT_RECRUITING
Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors nanUNKNOWN
Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors nanNOT_YET_RECRUITING
18F-LN1 PET/CT in Urothelial Carcinomas nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NECTIN4 binder may also engage these)

ProteinNameSimilarity
Q8R007 — 1.000 Q8R007 →
Q5E9Z9 — 1.000 Q5E9Z9 →
P32507 — 0.993 P32507 →
Q92692 — 0.990 Q92692 →
P50895 — 0.990 P50895 →
Q9MZ08 — 0.987 Q9MZ08 →
Q9R069 — 0.984 Q9R069 →
Q6UWL6 — 0.983 Q6UWL6 →
Q7TSU7 — 0.982 Q7TSU7 →
Q9ESS6 — 0.982 Q9ESS6 →
Q05BQ1 — 0.979 Q05BQ1 →
Q9JKF6 — 0.979 Q9JKF6 →
AXL Tyrosine-protein kinase receptor UFO 0.979 landscape →
Q9P2J2 — 0.978 Q9P2J2 →
P43121 — 0.978 P43121 →
Q8N0Z9 — 0.976 Q8N0Z9 →
Q8IZU9 — 0.975 Q8IZU9 →
Q8BR86 — 0.975 Q8BR86 →
Q5STE3 — 0.975 Q5STE3 →
P15151 — 0.975 P15151 →
Q9GL76 — 0.974 Q9GL76 →
Q15223 — 0.974 Q15223 →
Q6MZW2 — 0.974 Q6MZW2 →
Q96AP7 — 0.973 Q96AP7 →
Q1WIM1 — 0.973 Q1WIM1 →
P32506 — 0.972 P32506 →
P0C5H6 — 0.972 P0C5H6 →
Q0VCN6 — 0.972 Q0VCN6 →
P27930 — 0.971 P27930 →
Q9WUL5 — 0.971 Q9WUL5 →